WilliamJosephJohnMD

PubMed

• 13 citations
  Abemaciclib in Combination with Single-Agent Options in Patients with Stage IV Non-Small Cell Lung Cancer: A Phase Ib Study.
  Edward S. Kim, Karen Kelly, Luis Paz-Ares, Pilar Garrido, Shadia I. Jalal
  Clinical Cancer Research. 2018-11-15
• 201 citations
  KRAS-Mutant non-small cell lung cancer: From biology to therapy.
  Irene Ferrer, Jon Zugazagoitia, Stephan Herbertz, William J. John, Luis Paz-Ares
  Lung Cancer. 2018-07-19
• 5 citations
  Evaluation of changes in renal function in PARAMOUNT: a phase III study of maintenance pemetrexed plus best supportive care versus placebo plus best supportive care af...
  Gary Middleton, Cesare Gridelli, Filippo de Marinis, Jean-Louis Pujol, Martin Reck
  Current Medical Research and Opinion. 2018-03-27

Journal Articles

• Meta-Analysis examining impact of age on overall survival with pemetrexed for the treatment of advanced non-squamous non-small cell lung cancer  
  Paz-Ares L, Zimmerman A, Ciuleanu T, Bunn P, San Antonio B, Denne J, Iturria N, John WJ, and Scagliotti G, Lung Cancer, 1/1/2017
• Treatment patterns and cost effectiveness of the first-line treatment of advanced nonsquamous non-small cell lung cancer in Medicare patients  
  Gildon DM, Kubisiak JM, Pohl GM, Ball DE, Gilden DE, John WJ, Wetmore S, and Winfree KB, J Med Oncol, 1/1/2016
• Patient-Reported pain and other quality of life domains as prognostic factors for survival in a phase III clinical trial of patients with advanced breast cancer  
  Smyth E, Shen W, Bowman L, Peterson P, John WJ, Melemed A, and Liepa A, Health and Quality of Life Outcomes, 1/1/2016
• Analysis of pemetrexed plus carboplatin doublet safety profile in first line non-squamous non-small cell lung cancer (NSCLC) studies  
  Okamoto I, Schuette W, Stinchcombe T, Pereira J, Lui J, San Antonio B, John WJ, Chen J, and Zinner R, Curr Med Rev Opin, 1/1/2016
• Safety profiles of non-small cell lung cancer patients treated with pemetrexed plus carboplatin: A real world experience  
  Chen L, Goodloe R, Yan Y, John WJ, Chen J, and San Antonio B, Curr Med Rev Opin, 1/1/2016
• Adverse events in patients with advanced non-small cell lung cancer: Findings from IMS Oncology, a US Oncology electronic medical record  
  Chen L, San Antonio B, Swain JL, Mitchell L, John WJ, Akoub H, Michael J, Marmaduke DQ, and Yuer Y, Pharmacoepidemiology and Drug Safety, 1/1/2015
• PARAMOUNT: Descriptive subgroup analysis of final overall survival for the phase III study of maintenance pemetrexed vs placebo following induction treatment with peme...  
  Reck M, Paz-Ares L, de Marinis F, Molinier O, Sahoo TP, Laack E, John WJ, Zimmerman A, Visseren-Grul C, and Gridelli C, J Thorac Oncol, 1/1/2014
• Final efficacy and safety results of pemetrexed continuation maintenance in the elderly from the PARAMOUNT phase III study  
  Gridelli C, de Marinis F, Thomas M, Prabhash K, El Kouri C, Blackhall F, Bustin F, Pujol JL, John WJ, San Antonio B, Zimmerman A, Choudaki N, Visseren-Grul C, and Paz-..., J Thorac Oncol, 1/1/2014
• A comprehensive review of non-genetic prognostic and predictive factors influencing the heterogeneity of outcomes in advanced non-small cell lung cancer  
  Carter GC, Barrett AM, Kaye JA, Liepa AM, Winfree KB, and John WJ, Cancer Manag Res, 1/1/2014
• Final overall survival results of the phase III study of maintenance pemetrexed versus placebo immediately following induction treatment with pemetrexed plus cisplatin...  
  Paz-Ares L, de Martinis F, Dediu M, Thomas M, Pujol JL, Bidoli P, Molinier O, Sahoo T, Laack E, Reck M, Corral J, Melemed S, John W, Choudiak N, Zimmerman A, Visseren-..., J Clin Oncol, 1/1/2013
• PointBreak: A Randomized Phase III Study of Pemetrexed Plus Carboplatin and Bevacizumab Followed by Maintenance Pemetrexed and Bevacizumab Versus Paclitaxel Plus Carbo...  
  Patel JD, Socinski MA, Garon E, Reynolds CH, Spigel DR, Olsen MR, Hermann RC, Jotte RM,Beck T, Richards DA, Guba SC, Liu J, Frimodt-Moller B, John WJ, Obasaju CK, Penn..., J Clin Oncol, 1/1/2013
• Indentifying the target NSCLC patient for maintenance therapy: An analysis from a placebo controlled phase III trial of maintenance pemetrexed  
  Obasaju C, Bowman L, Shen W, Wang P, John W, Winfree K, Nash-Smyth E, Broderwicz T, Belani C, Ann Oncol, 1/1/2013
• Maintenance Treatment: Results from a randomized phase III study of pemetrexed vs placebo  
  Belani CE, Brodowicz T, Ciuleanu TE, Krzakowski M, Yang SH, Franke F, Cucevic B, Madhavan J, Santoro A, Ramlau R< Liepa AM, Visseren-Grul C, Peterson P, John WJ, Zi..., Lancet Oncol, 1/1/2012
• PARAMOUNT: Phase III study of maintenance Pemetrexed plus best supportive care versus placebo plus best supportive care following induction treatment with pemetrexed p...  
  Paz-Ares L, de Martinis F, Dediu M, Thomas M, Pujol JL, Bidoli P, Molinier O, Sahoo T, Laack E, Reck M, Corral J, Melemed S, John W, Choudiak N, Zimmerman A, Visseren-..., Lancet Oncol, 1/1/2012
• Safety, resource use, and quality of life in PARAMOUNT: A phase III study of maintenance pemetrexed versus placebo after induction pemetrexed plus cisplatin for advanc...  
  Gridelli C, de Marinis F, Pujol J-L, Reck M, Ramlau R, Parente B, Pieters T, Middleton G, Winfree K, Melemed S, Zimmermann A, John W, Beyrer J, Chouski NVisseren-Grul ..., J Thor Oncol, 1/1/2012
• Maintenance pememtrexed plus best supportive care vs placebo plus best supportive care for non-small cell lung cancer: A randomized double-blind phase III study  
  Ciuleanu T, Brodowicz T, Zielinski C, Kim JH, Krzakowski M, Laack E, Wu YL, Bover I, Begbie S, Tzekova V, Cucevic B, Pereira JR, Yang SH, Madhavan J, Sugarman KP, Pete..., Lancet, 1/1/2009
• Phase III study of gemcitabine and cisplatin with or without aprinocasen an antisense oligonucleotide in patients with advanced stage non small cell lung cancer  
  Paz-Ares L, Doulliard JY, Koralewski P, Manegold C, Smit E, John WJ, Peterson P, Obasaju C, Lahn M, Gandara D, J Clin Oncol, 1/1/2006
• Pemetrexed and oxaliplatin for first-line treatment of patients with advanced colorectal cancer: a phase II trial of the NSABP foundation research program  
  Atkins J, Jacobs S, Wieand S, Smith R, John WJ, Colangelo L, Geyer C, Wolmark N, Clin Colorectal Cancer, 1/1/2005
• A phase III trial of pemetrexed plus gemcitabine versus gemcitabine in patients with unresectable or metastatic pancreas cancer  
  Oettle H, Richards D, Ramanathan RK, van Laethem JL, Peeters M, Fuchs M, Zimmerman A, John WJ, von Hoff D, Arning M, Kindler H, Ann Oncol, 1/1/2005
• Preoperative chemoradiation in fixed distal rectal cancer: Dose time factors for pathological complete response  
  Mohiuddin M, Regine WF John WJ, Hagihara PF, McGrath PC, Kenady DE, Marks G, Int J Radiation Oncology Biol Phys, 1/1/2000
• Results of high-dose intra-arterial (IA) cisplatin and concurrent hyperfractionated radiation therapy (HFX-RT) in patients with high volume unfavorable squamous cell c...  
  Regine WF, Valentino J, John WJ, Storey G, Patel P, Sloan D, Kenady D, Pulmano C, Abner J, Mohiuddin M, Head Neck, 1/1/2000
• Activity of MTA (LY 231514) in patients with advanced colorectal cancer: Report of a phase II study  
  John WJ, Clark J, Burris H, Picus J, Schulman L, Thornton D, Loehrer P, Cancer, 1/1/2000
• A phase II trial of multi-targeted antifolate (MTA) (LY231514) in patients with unresectable pancreatic cancer  
  Miller KD, Loehrer PJ, Picus J, Blanke C, John WJ, Clark J, Schulman LN, Burris H, Thornton D, Ann Oncol, 1/1/2000
• Clinical and immune responses in surgically resected colorectal cancer (CRC) patients treated with anti-idiotype antigen (CEA) with or without fluorouracil (5-FU)  
  Foon KA, John WJ, Chakraborty M, Garrison J, Bard M, Bhattachary-Chatterjee M, J Clin Oncol, 1/1/1999
• Adjuvant therapy for pancreas cancer: Current status  
  Regine WF, John WJ and Mohiuddin M, Frontiers in Bioscience, 1/15/1998
• Join now to see all